IL6 and Miyoshi myopathy: Siltuximab (CNTO328) is a chimeric anti-IL-6 mAb that was shown to enhance the cytotoxic effect of melphalan, dexamethasone, or bortezomib with dexamethasone in MM cell lines and in cells from refractory MM patients [169,170].